- PCaTest
has already proven a superior predictive ability in comparison with other
genetic prognostic tests
- Cytodyn
in the process of acquiring PCaTest developer ProstaGene and will launch a
clinical study once the transaction is complete
- Prostate
cancer is the second-most common type of cancer among American men, with
almost 165,000 new cases expected this year
Biotechnology company CytoDyn Inc. (OTCQB: CYDY) has
unveiled a comprehensive strategy for the development of a genetic prostate
cancer prognostic test (http://ibn.fm/GSEfb).
Developed by ProstaGene, an entity that CytoDyn is in the process of acquiring,
PCaTest has already demonstrated superior predictive ability in comparison to
other genetic prostate cancer tests. The PCaTest employs 14 genetic biomarkers
to provide an accurate prognosis of prostate cancer, with the help of a complex
proprietary artificial intelligence algorithm.
Following the completion of the ProstaGene acquisition,
which is expected to close during the fourth quarter of 2018, CytoDyn will
initiate a clinical study aimed at establishing the superior qualities of the
PCaTest compared with current genetic tests. CytoDyn expects research results
within four months from the start of the clinical trial.
CytoDyn interim Chief Medical Officer Richard Pestell, developer
of the PCaTest, said in a news release that, so far, this test has shown three
to four times superior hazards ratio (a predictor of outcome) in comparison to
other prognostic tests for prostate cancer. The statement is based on results
from three studies (featuring a total of 348 patient samples).
Recent evidence raises concerns about the ability of current
prognostic tests to distinguish whether prostate cancer will be aggressive or
slowly growing, Pestell said. Such vital information about the makeup of the
malignancy can be used by physicians to make adequate decisions about the
treatment of a patient.
Tests available now rely on the detection of
prostate-specific antigen (PSA). Elevated PSA in the blood provides a warning,
but it is not 100 percent indicative of cancer. Patients who have high PSA
levels detected multiple times need to undergo a prostate biopsy to confirm the
existence of cancer. During the biopsy, 12 extracted tissue samples are used
for standard testing. In the case of the PCaTest, a single sample will be
sufficient.
CytoDyn President and CEO Nader Pourhassan said that his
company plans to complete development of the PCaTest soon and with minimal cost
to CytoDyn, so as to file for Food and Drug Administration approval in 2019.
Prostate cancer is a common ailment in older men, and, as
the Western population ages, the incidence of this malignancy is expected to
increase. According to a forecast presented in the European Urology journal,
the incidence of prostate cancer will double by 2030 (http://ibn.fm/Khd2L).
Early screening is effective for certain types of cancer,
including prostate cancer, according to the American Cancer Society (http://ibn.fm/THygV). Frequent
PSA screening every four years can significantly lower the risk of death from
prostate cancer. This type of cancer typically grows very slowly, which helps
with early detection and allows urologists to administer an adequate treatment.
Currently, apart from skin cancer, prostate cancer is the
most common malignancy in American men (http://ibn.fm/pkFk1). In 2018, some 164,690 new cases of
prostate cancer are expected to be diagnosed. The number of deaths from this
malignancy is forecast to reach 29,430 during the year. At the same time, the
five-year survival rate for patients diagnosed with early stage prostate cancer
is 100 percent.
CytoDyn is a biotech company that develops a novel humanized
CCR5 monoclonal antibody, PRO 140, for multiple therapeutic indications. The
CCR5 receptor plays a vital role in the ability of HIV to enter and infect
T-cells. It is also implicated in the metastasis of tumors, as well as
immune-mediated illnesses. CytoDyn’s lead product candidate, PRO 140, is in
advanced clinical development for the treatment of HIV in combination with
other anti-retroviral therapeutics and also as a potential single-agent
treatment for HIV. The company is also conducting a Phase 2 clinical study of
PRO 140 as a potential treatment to prevent graft-versus-host disease following
bone marrow transplantation. CytoDyn further plans to conduct clinical
investigations with PRO 140 in the treatment of metastatic breast cancer,
following the completion of its acquisition of ProstaGene.
For more information, visit the company’s website at www.CytoDyn.com
About QualityStocks
QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential. We offer several ways for investors to learn more
about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment